 The most likely acquirer would be the type of Company that bought AbCam
i.e. Danaher
They bought AbCam for $5bn.
AbCam are rumoured to be a FAB client.
Would make sense the AbCam story was to have the most diverse catalogue of antibodies
WASHINGTON, Aug. 28, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Abcam plc (NASDAQ: ABCM), a leading global supplier of protein consumables, pursuant to which Danaher will acquire all of the outstanding shares of Abcam for $24.00 per share in cash, or a total enterprise value of approximately $5.7 billion including assumed indebtedness and net of acquired cash.
Founded in 1998 and headquartered in Cambridge, UK, Abcam offers the scientific community highly validated antibodies, reagents, biomarkers and assays to address targets in biological pathways that are critical for advancing drug discovery, life sciences research, and diagnostics. Its technologies are used by approximately 750,000 researchers.
Abcam is expected to operate as a standalone operating company and brand within Danaher's Life Sciences segment, furthering Danaher's strategy to help map complex diseases and accelerate the drug discovery process. |
Hopefully the NCI news will come out before any offers for FAB itself. |
Thiopia I think that’s a really interesting theory and absolutely agree with the generation of value (plus the potential for licencing agreements on their tech). Nothing to stop another CRO, competitor CRO snapping them up however. Or a large scale diagnostics or research antibody company taking them to expand their horizons into therapeutics though.
Look at Charles river snapping up distributed bio for a comparison as to what other CROs might pay for technology platforms |
I don't think any Big Pharma will buy FAB. FAB is like the ARM of the semiconductor industry it has more value as an independent third party player selling into the arms race between the various biotechs/pharmas.
Like ARM the long term value will be in the royalties/milestones they secure on IP/antibodies which eventually make it as therapeutics earning FAB a growing stream of income thanks to/leveraging the R&D and Sales & Marketing power of bios/Big Pharma |
..exciting prospect dandy, but is that your hope/ expectation... or is that fact?
If the latter who ..and what are your sources? |
Next news could actually be the last news as many big pharmaceutical companies lining up to bag FAB. |
This is how it moves without news... |
Not many trades so far today, but I'm getting a firm bid for over 3/4 million shares.
Definitely an appetite. |
As we approach April many businesses are contemplating redundancies to cover increased national insurance costs thanks to this stupid Labour government. The NI costs are going to be a real challenge for business and will have a real knock on effect to staffing as well as reducing profits. It is hard to believe that FAB must be one of the few UK companies that have already mitigated this risk and NI cost which has been covered in their new £6m grant funding. FAB has not only mitigated NI costs on future hires, it has actually covered the full cost of 20 employees PA for the next 5 years. This gives the business confidence to take on larger contracts as the resource is already funded therefore profits will bet skewed significantly to the upside thanks to this 5 year Grant for £6m. It must be a great comfort to the CEO and FD knowing they can shoot the lights out on top line revenue and overheads won't increase as a result. Really well done to whoever neg this grant as its much more lucrative than the market has given them credit for. We are also waiting on updates on the following -
Fusion Antibodies expanded its collaboration with the National Cancer Institute to include humanization services for existing camelid nanobodies.
- They secured a new contract for an antibody-based therapeutic with an unnamed US-based biotechnology company.
- They also undertook the development of a bespoke OptiPhage library for an unnamed client.
When you consider the AI library / technology, Pharma partners like GSK etc, / new fixed overheads that allow the business to scale rapidly , No debt and a CEO stressing they working towards cashflow breakeven without a raise then FAB for me is an excellent buy in this sector especially when you consider other sectors that will need to deal with sever headwinds from this labour government. |
Lots of converging trend lines, all being retested after the spike above them all, lower volumes each day, looking like we could see another lift off moment soon, although I have to say looks like next week now before any news...
free stock charts from uk.advfn.com |
Charts not really my thing, but if they were, I'd volunteer that there is very little resistance between current level (ok maybe halfp higher) and 30p. All it will need is for the touch paper to be lit for a reversal/rerate back to mid 2023 levels.
The reversal could be very quick and the catalyst could come from one of many positive directions. |
Yes. Looks like a Bull Flag or Pennant building up strength for the potential move from 10p to 30p-40p range looks do-able depending on news etc
I don't think a £30-40m Mkt Cap (with £6m of non-dilutive funding just secured) is outlandish for a Company which can produce an antibody sold for $400m ! or with comparators like FairJourney ($900m) and AbSci ($450m)
Indeed I expect 30-40p to be just the start of the journey back to 100p and above.
Strikes me also as a stock which Institutional Investors with memory of the AbCam story should be all over ! |
Not knowing much about these things, but are we seeing another of those flaggy things forming?... (and the UT at the end higher than mid all day - helping the formation)
Hope I'm not being pennantic? :-) |
Looking to re test 11.75 again this week pre news |
Slowly working its way back to read 11.75 again. |
Lots of overplaying the potential just before the hundreds of trades to push the share price higher.
Why not wait to see what the company has to say? |
Exactly thiopia. The life Science sector is going through a brisk period of M&A activity. Im sure FAB will be on multiple radars - |
Amazing how the HVO rampers were also claiming a 100p over there.
That is still crashing down, even today...
Is it a coincidence that thread has gone quiet and this one busy???
Same pump and dump gang??? |
Great spot above. I imagine the Companies interested in FAB will be multiples bigger than Charles River and will be prepared to pay multiples higher for FAB than Charles River have paid for the 'SuperHuman' Antibody company
The US National Cancer Institute will play a big part in validating FAB platform and will determine what multiple of 100p we eventually see here. IMO. |
Posted on LSE - Just confirms we are looking at a quid min for a FAB takeover
Today 13:37
Imagine the fab optiphage client decides they want that whole technology - could be around this value maybe - that was just to get access to one platform and fab have multiple ones |
Next news should be this month on various fronts. Won't be 10p for long . Short term target 35 |
Jeanesy,
There's always be traders and profit takers.
The point is interims were 2 months ago and the Grant rns was over a month ago. Therefore, known about months ago.
I think it'll be sometime, months before everything mentioned in the Grant rns is setup, integrated.
Currently, I think there's a lot of churning by existing holders. |
Someone clearly interested in scooping up undervalued shares and waiting for the dips. Very interesting |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
